Nuvectis Pharma Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	-22.38	-22.26	-19.09	-12.89	-0.02
Stock-Based Compensation	4.6	4.71	1.71	1.89	-
Change in Accounts Payable	-0.34	-0.14	1.85	1.59	0.02
Change in Other Net Operating Assets	2.59	1.74	1.97	-0.09	-
Operating Cash Flow	-15.54	-15.95	-13.56	-9.5	-
Issuance of Common Stock	20.63	16.48	31.88	-	-
Other Financing Activities	-1.1	-1.39	-4.07	-	-
Financing Cash Flow	19.53	15.09	27.81	15.25	-
Net Cash Flow	4	-0.87	14.25	5.74	-
Free Cash Flow	-15.54	-15.95	-13.56	-9.5	-
Free Cash Flow Per Share	-0.97	-1.03	-1.07	-2.23	-
Levered Free Cash Flow	-7.02	-7.83	-6.12	-	-
Unlevered Free Cash Flow	-7.02	-7.83	-6.12	-	-
Change in Net Working Capital	-2.25	-1.15	-3.45	-	-

Source: S&P Capital IQ. Standard template.